EE136 Cost-Effectiveness Analysis of Tisagenlecleucel Using Long-Term Survival Outcomes in Treating Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma from US Societal Perspective

We evaluated the cost-effectiveness of Tisagenlecleucel (CD19CAR-T cells) versus salvage chemotherapy followed by hematopoietic cell transplantation in treating diffuse large b-cell lymphoma (DLBCL) patients who are refractory or relapsed after 2 or more lines of therapy from the US societal perspective.